Kindred Biosciences (KIN) Stock Price, News & Analysis

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Key Stats

• Today's Range: $9.24 to $9.26
• 50-Day Range: $9.08 to $9.25
• 52-Week Range: $3.46 to $9.28
• Volume: 178,496 shs
• Average Volume: 840,890 shs
• Market Capitalization: $420.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KIN Stock Analysis - Frequently Asked Questions

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analyst estimates of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 6/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KIN
• CIK: 1561743
• Web: kindredbio.com
• Phone: (650) 701-7901
• Fax: N/A
• Employees: 63
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.80 million
• Net Margins: -529.26%
• Pretax Margin: N/A
• Return on Equity: -54.19%
• Return on Assets: -39.76%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: $42.16 million
• Price / Sales: 9.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 45,462,000
• Free Float: N/A
• Market Cap: $420.52 million
• Optionable: Optionable
• Beta: 1.30